Drugs / Neuronox
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04113941 | Aug 2019 → Apr 2020 | overactive bladder | Medy-Tox | Unknown | No outcome recorded |
| Phase 3 | NCT03216473 | May 2016 → Mar 2017 | benign essential blepharospasm | Medy-Tox | Completed | No outcome recorded |
| Phase 3 | NCT03216408 | Mar → Nov 2016 | — | Medy-Tox | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neuronox | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04113941 ↗ |
| Modality | Protein / enzyme biologic | “Botulinum toxin type A for Injection” NCT03216408 ↗ |
| Route | Other | “intradetrusor injection” NCT04113941 ↗ |